

Watson Pharmaceuticals, Inc., a leader in generic and specialty branded pharmaceuticals, announced that the US Food and Drug Administration (FDA) has approved Gelnique (oxybutynin chloride) gel 10 per cent, the first and only topical gel for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and frequency.

[read more](#)